S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Calliditas Therapeutics AB (publ) (CALT) Short Interest Ratio & Short Volume

$18.70
+1.05 (+5.95%)
(As of 04/19/2024 ET)

Calliditas Therapeutics AB (publ) Short Interest Data

Current Short Volume
3,200 shares
Previous Short Volume
7,300 shares
Change Vs. Previous Month
-56.16%
Dollar Volume Sold Short
$67,232.00
Short Interest Ratio / Days to Cover
0.4
Last Record Date
March 31, 2024
Outstanding Shares
29,790,000 shares
Percentage of Shares Shorted
0.01%
Today's Trading Volume
4,017 shares
Average Trading Volume
5,387 shares
Today's Volume Vs. Average
75%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Calliditas Therapeutics AB (publ) ?

Sign up to receive the latest short interest report for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

CALT Short Interest Over Time

CALT Days to Cover Over Time

CALT Percentage of Float Shorted Over Time

Calliditas Therapeutics AB (publ) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/31/20243,200 shares $67,232.00 -56.2%N/A0.4 $21.01
3/15/20247,300 shares $163,958.00 +15.9%N/A0.5 $22.46
2/29/20246,300 shares $134,312.85 +37.0%N/A0.4 $21.32
2/15/20244,600 shares $94,668.00 -20.7%N/A0.3 $20.58
1/31/20245,800 shares $132,588.00 No ChangeN/A0.4 $22.86
1/15/20245,800 shares $145,000.00 -43.1%N/A0.4 $25.00
12/31/202310,200 shares $262,588.80 +20.0%N/A0.6 $25.74
12/15/20238,500 shares $187,765.00 -29.2%N/A0.6 $22.09
11/30/202312,000 shares $208,200.00 +26.3%N/A1.1 $17.35
11/15/20239,500 shares $161,215.00 +93.9%N/A0.9 $16.97
10/31/20234,900 shares $79,870.00 +63.3%N/A0.5 $16.30
10/15/20233,000 shares $52,050.00 -21.1%N/A0.3 $17.35
9/30/20233,800 shares $69,388.00 +40.7%N/A0.4 $18.26
9/15/20232,700 shares $43,104.42 -34.2%N/A0.3 $15.96
8/31/20234,100 shares $72,652.00 -48.1%N/A0.6 $17.72
8/15/20237,900 shares $152,707.00 +315.8%N/A1.1 $19.33
7/31/20231,900 shares $37,050.00 -24.0%N/A0.3 $19.50
7/15/20232,500 shares $40,125.00 +4.2%N/A0.4 $16.05
6/30/20232,400 shares $37,680.00 -51.0%N/A0.4 $15.70
6/15/20234,900 shares $89,363.75 -41.7%N/A0.8 $18.24
5/31/20238,400 shares $143,304.00 +47.4%N/A0.8 $17.06
5/15/20235,700 shares $145,350.00 +128.0%N/A0.5 $25.50
4/30/20232,500 shares $58,350.00 -77.3%N/A0.2 $23.34
4/15/202311,000 shares $272,250.00 -16.0%N/A0.8 $24.75
3/31/202313,100 shares $314,007.00 -42.3%N/A0.9 $23.97
3/15/202322,700 shares $572,948.00 +58.7%N/A1.6 $25.24
2/28/202314,300 shares $264,693.00 +346.9%N/A1.4 $18.51
2/15/20233,200 shares $57,472.00 +10.3%N/A0.3 $17.96
1/31/20232,900 shares $55,680.00 -52.5%N/A0.3 $19.20
1/15/20236,100 shares $120,780.00 -38.4%N/A0.6 $19.80
12/30/20229,900 shares $168,300.00 +67.8%N/A0.9 $17.00
12/15/20225,900 shares $115,616.40 -38.5%N/A0.5 $19.60
11/30/20229,600 shares $174,432.00 +37.1%N/A0.8 $18.17
11/15/20227,000 shares $115,500.00 +25.0%N/A0.7 $16.50
10/31/20225,600 shares $83,440.00 +60.0%N/A0.6 $14.90
10/15/20223,500 shares $54,600.00 -59.3%N/A0.4 $15.60
9/30/20228,600 shares $130,428.46 +230.8%N/A1.4 $15.17
9/15/20222,600 shares $41,106.00 -27.8%N/A0.5 $15.81
8/31/20223,600 shares $59,400.00 -49.3%N/A0.8 $16.50
8/15/20227,100 shares $153,005.00 +4.4%N/A1.4 $21.55
A.I. Pioneer Issues Urgent Warning to Americans (Ad)

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

CALT Short Interest - Frequently Asked Questions

What is Calliditas Therapeutics AB (publ)'s current short interest?

Short interest is the volume of Calliditas Therapeutics AB (publ) shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 3,200 shares of CALT short. Learn More on Calliditas Therapeutics AB (publ)'s current short interest.

Which institutional investors are shorting Calliditas Therapeutics AB (publ)?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Calliditas Therapeutics AB (publ): Citadel Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Calliditas Therapeutics AB (publ)'s short interest increasing or decreasing?

Calliditas Therapeutics AB (publ) saw a decline in short interest in March. As of March 31st, there was short interest totaling 3,200 shares, a decline of 56.2% from the previous total of 7,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Calliditas Therapeutics AB (publ)'s short interest compare to its competitors?

Here is how the short interest of companies in the sector of "medical" compare to Calliditas Therapeutics AB (publ): Arbutus Biopharma Co. (2.53%), Phibro Animal Health Co. (3.49%), Altimmune, Inc. (25.01%), Acelyrin, Inc. (13.03%), IGM Biosciences, Inc. (25.10%), COMPASS Pathways plc (5.05%), KalVista Pharmaceuticals, Inc. (13.08%), Applied Therapeutics, Inc. (4.70%), Oculis Holding AG (0.17%), AnaptysBio, Inc. (18.16%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

What does it mean to sell short Calliditas Therapeutics AB (publ) stock?

Short selling CALT is an investing strategy that aims to generate trading profit from Calliditas Therapeutics AB (publ) as its price is falling. CALT shares are trading up $1.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Calliditas Therapeutics AB (publ)?

A short squeeze for Calliditas Therapeutics AB (publ) occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CALT, which in turn drives the price of the stock up even further.

How often is Calliditas Therapeutics AB (publ)'s short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CALT, twice per month. The most recent reporting period available is March, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:CALT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners